Gilead’s Twice-Yearly Lenacapavir 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

 – First Phase 3 HIV Prevention Trial Ever to Show Zero Infections –

– Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants –

https://www.businesswire.com/news/home/20240620044585/en